Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses.
A large number of unwanted adverse events and symptoms reported by patients in clinical trials are not caused by the drug provided, since most of adverse events also occur in corresponding placebo groups. These nocebo effects also play a major role in drug discontinuation in clinical practice, negat...
主要な著者: | Laura Wendt, Antje Albring, Sven Benson, Harald Engler, Andrea Engler, Anke Hinney, Winfried Rief, Oliver Witzke, Manfred Schedlowski |
---|---|
フォーマット: | 論文 |
言語: | English |
出版事項: |
Public Library of Science (PLoS)
2014-01-01
|
シリーズ: | PLoS ONE |
オンライン・アクセス: | http://europepmc.org/articles/PMC4164653?pdf=render |
類似資料
-
Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond.
著者:: Tunbridge, E, 等
出版事項: (2006) -
VAL158MET catechol O-methyltransferase polymorphism contributes to the development of preeclampsia
著者:: Tamara Sljivancanin Jakovljevic, 等
出版事項: (2020-10-01) -
Subjective reward processing and catechol-O- methyltransferase Val158Met polymorphism as potential research domain criteria in addiction: A pilot study
著者:: Nico Rohlfing, 等
出版事項: (2022-10-01) -
Human plasma homocysteine levels are associated with the catechol-O-methyltransferase Val158Met polymorphism
著者:: Tunbridge, E, 等
出版事項: (2007) -
Association between the Catechol O-methyltransferase (COMT) Val158met polymorphism and different dimensions of impulsivity.
著者:: Leandro Fernandes Malloy-Diniz, 等
出版事項: (2013-01-01)